A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations

Area of Science:

• Pharmacokinetics and Pharmacodynamics
• Infectious Diseases
• Clinical Pharmacy

Background:

• Effective treatment of complicated methicillin-resistant Staphylococcus aureus (MRSA) infections with vancomycin necessitates achieving a 24-hour area under the concentration-time curve (AUC24) to minimum inhibitory concentration (MIC) ratio of ≥400.
• Current methods to achieve target AUC24 involve risking nephrotoxicity, measuring patient-specific pharmacokinetics, or employing Bayesian statistics, which are complex or potentially harmful.
• There is a need for a simpler, safer method to guide vancomycin dosing for MRSA infections.

Purpose of the Study:

• To present a novel method for determining patient-specific vancomycin pharmacokinetics using only trough measurements.
• To optimize vancomycin dosing to achieve therapeutic AUC24 targets while minimizing nephrotoxic concentrations.
• To evaluate the accuracy and reliability of this trough-guided method compared to conventional dosing strategies via simulation.

Main Methods:

• A Monte Carlo simulation of 10,000 patients with complicated MRSA infections was conducted using two-compartment pharmacokinetic models derived from literature data.
• Patient-specific pharmacokinetics were determined using consecutive trough concentrations, and accuracy was compared to the traditional peak-trough method.
• A strategy to resolve simulated trough timing errors using iteration was developed and tested.

Main Results:

• The proposed consecutive trough method demonstrated higher accuracy in determining patient-specific pharmacokinetics than the peak-trough method for peaks measured within 4 hours post-infusion.
• Simulated trough timing errors reduced accuracy, but an iterative approach effectively resolved these errors during loading or steady-state dosing.
• Both the simulated minimized concentration strategy and trough-based dosing (15-20 mg/L) showed a high probability of achieving the target AUC24 ≥400 mg·h/L, with lower risk of toxicity compared to conventional trough-based dosing.

Conclusions:

• The proposed trough-guided method offers a potentially simpler and safer approach to optimizing vancomycin dosing for MRSA infections, aiming for therapeutic efficacy while mitigating nephrotoxicity.
• The simulation results suggest this strategy is a viable alternative to existing AUC24-based approaches, though validation in clinical practice is essential.
• Further validation in real-world patient populations is required to confirm the clinical utility and safety of this dosing strategy before widespread adoption.